Britain’s biotech sector boasts the strongest new drug pipeline in Europe but industry leaders say it needs continued access to global talent, funding and regulatory clarity to thrive in the future – all of which could be jeopardized by Brexit.
A new report on Wednesday showed Britain was well ahead of rivals like Germany, France and Switzerland in terms of the number of experimental drugs in clinical development at early-stage biotech firms.
British biotech companies also topped the charts in venture capital financing, receiving more than a third of the total raised across Europe and more than any other European country, the report by trade group BioIndustry Association (BIA) found.
But there are serious challenges ahead, with sentiment cooling toward biotech investments after a record stock market run that peaked in 2015 and Britain’s decision to leave the European Union by 2019 adding to anxiety.
The BIA report showed a total of 1.13 billion pounds ($1.47 billion) was raised by UK-based biotech companies in 2016, down from an all-time high of 1.88 billion pounds in 2015.
Cash raised from initial public offerings (IPOs) was significantly lower at 105 million pounds, down from 307 million in 2015, and five out of the seven IPOs in 2016 happened before the EU referendum.
Venture capital funding, however, held up well, bolstered by inflows from veteran fund manager Neil Woodford, whose funds invested nearly half the 681 million pounds ploughed into the industry last year.
Significantly, Britain and non-EU member Switzerland accounted for 1.065 billion pounds of biotech venture funding in 2016, against 860 million for the rest of Europe combined.
Still, industry leaders are concerned at the potential loss of pivotal investment from the European Investment Bank and its European Investment Fund as a result of Brexit, leaving a funding gap that may have to be filled from inside Britain.
Another big Brexit worry is the future of drug regulation, with Britain set to leave the European Medicines Agency network, creating uncertainty over the approval of new medicines and the monitoring of existing ones in Britain.
“We need clarity on how medicines regulation is going to work post-Brexit and we would like to be closely aligned to the European system,” Bates said.
Stricter immigration rules in Brexit Britain are a further headache for industry executives and investors, given biotechnology’s reliance on global talent.
“Any Brexit settlement that limits our ability to recruit entrepreneurial scientists, physicians and leading biotech executives would have a devastating impact on the growth and success of the UK biotech sector,” said Kate Bingham, managing partner at SV Health Investors.
(Editing by Mark Potter)